BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wright AA, Howitt BE, Myers AP, Dahlberg SE, Palescandolo E, Van Hummelen P, MacConaill LE, Shoni M, Wagle N, Jones RT. Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer. 2013;119:3776-3783. [PMID: 24037752 DOI: 10.1002/cncr.28288] [Cited by in Crossref: 177] [Cited by in F6Publishing: 191] [Article Influence: 17.7] [Reference Citation Analysis]
Number Citing Articles
1 Luo H, Zhu Y, Wang J, Wang Y, Wei L. Comprehensive profile and contrastive analysis of circular RNA expression in cervical squamous carcinoma and adenocarcinoma. PeerJ 2023;11:e14759. [PMID: 36721776 DOI: 10.7717/peerj.14759] [Reference Citation Analysis]
2 Kusakabe M, Taguchi A, Tanikawa M, Hoshi D, Tsuchimochi S, Qian X, Toyohara Y, Kawata A, Wagatsuma R, Yamaguchi K, Yamamoto Y, Ikemura M, Sone K, Mori-Uchino M, Matsunaga H, Tsuruga T, Nagamatsu T, Kukimoto I, Wada-Hiraike O, Kawazu M, Ushiku T, Takeyama H, Oda K, Kawana K, Hippo Y, Osuga Y. Application of organoid culture from HPV18-positive small cell carcinoma of the uterine cervix for precision medicine. Cancer Med 2023. [PMID: 36691316 DOI: 10.1002/cam4.5588] [Reference Citation Analysis]
3 Momenimovahed Z, Mazidimoradi A, Maroofi P, Allahqoli L, Salehiniya H, Alkatout I. Global, regional and national burden, incidence, and mortality of cervical cancer. Cancer Reports 2022. [DOI: 10.1002/cnr2.1756] [Reference Citation Analysis]
4 Bin Saeed HA, Daghestani MH, Ambreen K, Daghestani MH, Al-zahrani SA, Alobaid H, Al-malahi NM. Low Dose of Green Synthesized Silver Nanoparticles is Sufficient to Cause Strong Cytotoxicity via its Cytotoxic Efficiency and Modulatory Effects on the Expression of PIK3CA and KRAS Oncogenes, in Lung and Cervical Cancer Cells. J Clust Sci 2022. [DOI: 10.1007/s10876-022-02395-3] [Reference Citation Analysis]
5 Grudzińska M, Jakubowska K, Lomperta K, Kańczuga-koda L, Wasilewska N, Żurakowska M, Koda M. The incidence of cervical intraepithelial neoplasia and its correlation with the results of histopathological examination in the female population of the Podlaskie Voivodeship. Diagn Lab 2022;58:59-65. [DOI: 10.5604/01.3001.0016.1346] [Reference Citation Analysis]
6 Chandra S, Goswami A, Mandal P. Molecular Heterogeneity of Cervical Cancer Among Different Ethnic/Racial Populations. J Racial Ethn Health Disparities 2022;9:2441-50. [PMID: 34741276 DOI: 10.1007/s40615-021-01180-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Sun Q, Wang L, Zhang C, Hong Z, Han Z. Cervical cancer heterogeneity: a constant battle against viruses and drugs. Biomark Res 2022;10:85. [DOI: 10.1186/s40364-022-00428-7] [Reference Citation Analysis]
8 Liu J, Li Z, Lu T, Pan J, Li L, Song Y, Hu D, Zhuo Y, Chen Y, Xu Q. Genomic landscape, immune characteristics and prognostic mutation signature of cervical cancer in China. BMC Med Genomics 2022;15:231. [DOI: 10.1186/s12920-022-01376-9] [Reference Citation Analysis]
9 Chandra S, Sarkar S, Mandal P. Identification of novel genetic and epigenetic regulators of different tissue types of cervical cancer. J Obstet Gynaecol Res 2022. [PMID: 36184073 DOI: 10.1111/jog.15454] [Reference Citation Analysis]
10 Ordulu Z, Mino-Kenudson M, Young RH, Van de Vijver K, Zannoni GF, Félix A, Burandt E, Wong A, Nardi V, Oliva E. Morphologic and Molecular Heterogeneity of Cervical Neuroendocrine Neoplasia: A Report of 14 Cases. Am J Surg Pathol 2022. [PMID: 36069807 DOI: 10.1097/PAS.0000000000001943] [Reference Citation Analysis]
11 Sun G, Zhang Q, Liu Y, Xie P, Liu Y. Role of Phosphatidylinositol 3-Kinase and Its Catalytic Unit PIK3CA in Cervical Cancer: A Mini-Review. Applied Bionics and Biomechanics 2022;2022:1-6. [DOI: 10.1155/2022/6904769] [Reference Citation Analysis]
12 Campos-parra AD, Pérez-quintanilla M, Martínez-gutierrez AD, Pérez-montiel D, Coronel-martínez J, Millan-catalan O, De León DC, Pérez-plasencia C. Molecular Differences between Squamous Cell Carcinoma and Adenocarcinoma Cervical Cancer Subtypes: Potential Prognostic Biomarkers. Current Oncology 2022;29:4689-4702. [DOI: 10.3390/curroncol29070372] [Reference Citation Analysis]
13 Horn L, Beckmann MW, Follmann M, Koch MC, Nothacker M, Pöschel B, Stübs F, Schmidt D, Höhn AK, Kommission zur Erstellung der S3-Leitlinie Zervixkarzinom. Revidierte Fassung der S3-Leitlinie Zervixkarzinom 2021 – Anforderungen an die Pathologie. Pathologie 2022;43:292-302. [DOI: 10.1007/s00292-021-01051-3] [Reference Citation Analysis]
14 Marvin DL, Spaans VM, de Kroon CD, Slieker RC, Khelil M, Ten Dijke P, Ritsma L, Jordanova ES. Low Transforming Growth Factor-β Pathway Activity in Cervical Adenocarcinomas. Front Oncol 2022;12:797453. [PMID: 35756604 DOI: 10.3389/fonc.2022.797453] [Reference Citation Analysis]
15 Stolnicu S, Soslow RA. Squamous and Glandular Epithelial Tumors of the Cervix: A Pragmatical Review Emphasizing Emerging Issues in Classification, Diagnosis, and Staging. Surg Pathol Clin 2022;15:369-88. [PMID: 35715166 DOI: 10.1016/j.path.2022.02.010] [Reference Citation Analysis]
16 Rose MM, Dhamodharan S, Revathidevi S, Chakkarappan SR, Mani JG, Shanmugam S, Nakaoka H, Inoue I, Murugan AK, Munirajan AK. High incidence of PI3K pathway gene mutations in South Indian cervical cancers. Cancer Genetics 2022. [DOI: 10.1016/j.cancergen.2022.05.002] [Reference Citation Analysis]
17 Maruthi VK, Khazaeli M, Jeyachandran D, Desouki MM. The Clinical Utility and Impact of Next Generation Sequencing in Gynecologic Cancers. Cancers (Basel) 2022;14:1352. [PMID: 35267660 DOI: 10.3390/cancers14051352] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Bhat A, Yadav J, Thakur K, Aggarwal N, Chhokar A, Tripathi T, Singh T, Jadli M, Veerapandian V, Bharti AC. Transcriptome analysis of cervical cancer exosomes and detection of HPVE6*I transcripts in exosomal RNA. BMC Cancer 2022;22:164. [PMID: 35148692 DOI: 10.1186/s12885-022-09262-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
19 Xiao ML, Wei Y, Zhang J, Jian JM, Song Y, Lin ZJ, Qian L, Zhang GF, Qiang JW. MRI Texture Analysis for Preoperative Prediction of Lymph Node Metastasis in Patients with Nonsquamous Cell Cervical Carcinoma. Acad Radiol 2022:S1076-6332(22)00021-6. [PMID: 35151550 DOI: 10.1016/j.acra.2022.01.005] [Reference Citation Analysis]
20 Kashofer K, Regauer S, Reich O, Petru E, Winter E. Driver gene mutations in micro-invasive cervical squamous cancers have no prognostic significance. Gynecol Oncol 2022:S0090-8258(22)00047-6. [PMID: 35101299 DOI: 10.1016/j.ygyno.2022.01.020] [Reference Citation Analysis]
21 Wen H, Guo QH, Zhou XL, Wu XH, Li J. Genomic Profiling of Chinese Cervical Cancer Patients Reveals Prevalence of DNA Damage Repair Gene Alterations and Related Hypoxia Feature. Front Oncol 2021;11:792003. [PMID: 35071000 DOI: 10.3389/fonc.2021.792003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Oh J, Jia T, Xu J, Chong J, Dervan PB, Wang D. RNA polymerase II trapped on a molecular treadmill: Structural basis of persistent transcriptional arrest by a minor groove DNA binder. Proc Natl Acad Sci U S A 2022;119:e2114065119. [PMID: 35022237 DOI: 10.1073/pnas.2114065119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
23 Shimada M, Tsuji K, Shigeta S, Nagai T, Watanabe Z, Tokunaga H, Kigawa J, Yaegashi N. Rethinking the significance of surgery for uterine cervical cancer. J Obstet Gynaecol Res 2021. [PMID: 34908207 DOI: 10.1111/jog.15112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Stolnicu S. Cervical cancer: what's new in classification, morphology, molecular findings and prognosis of glandular precursor and invasive lesions. Diagnostic Histopathology 2021;27:483-92. [DOI: 10.1016/j.mpdhp.2021.09.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Rowinski E, Magné N, Fayette J, Daguenet E, Racadot S, Pommier P, Méry B, Vallard A, Tinquaut F, Neidhardt-Berard EM, Cassier P, Attignon V, Pissaloux D, Wang Q, Sohier E, Pérol D, Blay JY, Trédan O. Radioresistance and genomic alterations in head and neck squamous cell cancer: Sub-analysis of the ProfiLER protocol. Head Neck 2021;43:3899-910. [PMID: 34643313 DOI: 10.1002/hed.26891] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Halle MK, Sundaresan A, Zhang J, Pedamallu CS, Srinivasasainagendra V, Blair J, Brooke D, Bertelsen BI, Woie K, Shrestha S, Tiwari H, Wong YF, Krakstad C, Ojesina AI. Genomic alterations associated with mutational signatures, DNA damage repair and chromatin remodeling pathways in cervical carcinoma. NPJ Genom Med 2021;6:82. [PMID: 34620846 DOI: 10.1038/s41525-021-00244-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Kuno I, Takayanagi D, Asami Y, Murakami N, Matsuda M, Shimada Y, Hirose S, Kato MK, Komatsu M, Hamamoto R, Okuma K, Kohno T, Itami J, Yoshida H, Shiraishi K, Kato T. TP53 mutants and non-HPV16/18 genotypes are poor prognostic factors for concurrent chemoradiotherapy in locally advanced cervical cancer. Sci Rep 2021;11:19261. [PMID: 34584128 DOI: 10.1038/s41598-021-98527-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
28 Zhu X, Xiang Z, Zou L, Chen X, Peng X, Xu D. APMAP Promotes Epithelial-Mesenchymal Transition and Metastasis of Cervical Cancer Cells by Activating the Wnt/β-catenin Pathway. J Cancer 2021;12:6265-73. [PMID: 34539899 DOI: 10.7150/jca.59595] [Reference Citation Analysis]
29 Choi S, Kim SW, Kim HS. Invasive Stratified Mucin-producing Carcinoma (ISMC) of the Uterine Cervix: Clinicopathological and Molecular Characteristics With Special Emphasis on the First Description of Consistent Programmed Death-ligand 1 (PD-L1) Over-expression. Cancer Genomics Proteomics 2021;18:685-98. [PMID: 34479920 DOI: 10.21873/cgp.20290] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Martínez-Rodríguez F, Limones-González JE, Mendoza-Almanza B, Esparza-Ibarra EL, Gallegos-Flores PI, Ayala-Luján JL, Godina-González S, Salinas E, Mendoza-Almanza G. Understanding Cervical Cancer through Proteomics. Cells 2021;10:1854. [PMID: 34440623 DOI: 10.3390/cells10081854] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
31 Chung TKH, Doran G, Cheung TH, Yim SF, Yu MY, Worley MJ Jr, Elias KM, Thorner AR, Pedamallu CS, Ojesina AI, Lau KM, Ducar MD, Wong RRY, Wang VW, Nag A, Wollison BM, Dalgarno A, Lee JHS, Yeung SY, Wong L, Horowitz NS, Davis MR, Leung SA, Mu Y, Mok SC, Chan PKS, Lawrence MS, Crum CP, Chiu RWK, Berkowitz RS, Wong YF. Dissection of PIK3CA Aberration for Cervical Adenocarcinoma Outcomes. Cancers (Basel) 2021;13:3218. [PMID: 34203201 DOI: 10.3390/cancers13133218] [Reference Citation Analysis]
32 Okonogi N, Ando K, Murata K, Wakatsuki M, Noda SE, Irie D, Tsuji H, Shozu M, Ohno T. Multi-Institutional Retrospective Analysis of Carbon-Ion Radiotherapy for Patients with Locally Advanced Adenocarcinoma of the Uterine Cervix. Cancers (Basel) 2021;13:2713. [PMID: 34072676 DOI: 10.3390/cancers13112713] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
33 Hodgson A, Howitt BE, Park KJ, Lindeman N, Nucci MR, Parra-Herran C. Genomic Characterization of HPV-related and Gastric-type Endocervical Adenocarcinoma: Correlation With Subtype and Clinical Behavior. Int J Gynecol Pathol 2020;39:578-86. [PMID: 31855952 DOI: 10.1097/PGP.0000000000000665] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 7.5] [Reference Citation Analysis]
34 Crowley FJ, O'Cearbhaill RE, Collins DC. Exploiting somatic alterations as therapeutic targets in advanced and metastatic cervical cancer. Cancer Treat Rev 2021;98:102225. [PMID: 34082256 DOI: 10.1016/j.ctrv.2021.102225] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
35 Kim N, Park W, Cho WK, Bae DS, Kim BG, Lee JW, Choi CH, Kim TJ, Lee YY. Significance of serum CA125 level in surgically resected cervical adenocarcinoma with adverse features. J Gynecol Oncol 2021;32:e72. [PMID: 34132070 DOI: 10.3802/jgo.2021.32.e72] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Jose S, Balakrishnan BR. Cervical Cancer Prevention and Treatment: An Overview. RJPT 2021. [DOI: 10.52711/0974-360x.2021.00415] [Reference Citation Analysis]
37 Shimada M, Sato S, Shoji T, Nagao S, Tokunaga H, Sueoka K, Takehara K, Nakamura K, Yamaguchi S, Kigawa J. Docetaxel and carboplatin chemotherapy for treating patients with stage IVB or recurrent non-squamous cell carcinoma of the uterine cervix: a phase II study. Int J Clin Oncol 2021;26:1314-21. [PMID: 33826028 DOI: 10.1007/s10147-021-01903-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
38 Lu S, Shi J, Zhang X, Kong F, Liu L, Dong X, Wang K, Shen D. Comprehensive genomic profiling and prognostic analysis of cervical gastric-type mucinous adenocarcinoma. Virchows Arch 2021. [PMID: 33817764 DOI: 10.1007/s00428-021-03080-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
39 Sharmin S, Zohura FT, Islam MS, Shimonty A, Khan MA, Parveen R, Sharmin F, Ahsan CR, Islam ABMMK, Yasmin M. Mutational profiles of marker genes of cervical carcinoma in Bangladeshi patients. BMC Cancer 2021;21:289. [PMID: 33736612 DOI: 10.1186/s12885-021-07906-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
40 Patrono MG, Calvo MF, Franco JVA, Garrote V, Vietto V. A systematic review and meta-analysis of the prevalence of therapeutic targets in cervical cancer. Ecancermedicalscience 2021;15:1200. [PMID: 33889209 DOI: 10.3332/ecancer.2021.1200] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
41 Stolnicu S, Park KJ, Kiyokawa T, Oliva E, McCluggage WG, Soslow RA. Tumor Typing of Endocervical Adenocarcinoma: Contemporary Review and Recommendations From the International Society of Gynecological Pathologists. Int J Gynecol Pathol 2021;40:S75-91. [PMID: 33570865 DOI: 10.1097/PGP.0000000000000751] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
42 Qin R, Cao L, Ye C, Wang J, Sun Z. A novel prognostic prediction model based on seven immune-related RNAs for predicting overall survival of patients in early cervical squamous cell carcinoma. BMC Med Genomics 2021;14:49. [PMID: 33588862 DOI: 10.1186/s12920-021-00885-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
43 Bosse T, Lax S, Abu-Rustum N, Matias-Guiu X. The Role of Predictive Biomarkers in Endocervical Adenocarcinoma: Recommendations From the International Society of Gynecological Pathologists. Int J Gynecol Pathol 2021;40:S102-10. [PMID: 33570867 DOI: 10.1097/PGP.0000000000000755] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
44 Segura S, Stolnicu S, Boros M, Park K, Ramirez P, Salvo G, Frosina D, Jungbluth A, Soslow RA. mTOR Pathway Activation Assessed by Immunohistochemistry in Cervical Biopsies of HPV-associated Endocervical Adenocarcinomas (HPVA): Correlation With Silva Invasion Patterns. Appl Immunohistochem Mol Morphol 2021;29:527-33. [PMID: 33587450 DOI: 10.1097/PAI.0000000000000915] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
45 Krishnamurthy S, Yoda H, Hiraoka K, Inoue T, Lin J, Shinozaki Y, Watanabe T, Koshikawa N, Takatori A, Nagase H. Targeting the mutant PIK3CA gene by DNA-alkylating pyrrole-imidazole polyamide in cervical cancer. Cancer Sci 2021;112:1141-9. [PMID: 33377228 DOI: 10.1111/cas.14785] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
46 Li W, Lei W, Chao X, Song X, Bi Y, Wu H, Wu M, Li L. Genomic alterations caused by HPV integration in a cohort of Chinese endocervical adenocarcinomas. Cancer Gene Ther 2021. [PMID: 33398034 DOI: 10.1038/s41417-020-00283-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
47 Stolnicu S. Epithelial Malignant Tumors of the Cervix: Endocervical Adenocarcinoma. Atlas of Diagnostic Pathology of the Cervix 2021. [DOI: 10.1007/978-3-030-49954-9_8] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
48 Watanabe T, Nanamiya H, Kojima M, Nomura S, Furukawa S, Soeda S, Tanaka D, Isogai T, Imai JI, Watanabe S, Fujimori K. Clinical implication of oncogenic somatic mutations in early-stage cervical cancer with radical hysterectomy. Sci Rep 2020;10:18734. [PMID: 33127935 DOI: 10.1038/s41598-020-72518-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
49 Xing D, Fadare O. Molecular events in the pathogenesis of vulvar squamous cell carcinoma. Semin Diagn Pathol 2021;38:50-61. [PMID: 33032902 DOI: 10.1053/j.semdp.2020.09.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
50 Gadducci A, Cosio S. Pharmacological Treatment of Patients with Metastatic, Recurrent or Persistent Cervical Cancer Not Amenable by Surgery or Radiotherapy: State of Art and Perspectives of Clinical Research. Cancers (Basel) 2020;12:E2678. [PMID: 32961781 DOI: 10.3390/cancers12092678] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
51 Yoshimoto Y, Sasaki Y, Murata K, Noda SE, Miyasaka Y, Hamamoto J, Furuya M, Hirato J, Suzuki Y, Ohno T, Tokino T, Oike T, Nakano T. Mutation profiling of uterine cervical cancer patients treated with definitive radiotherapy. Gynecol Oncol 2020;159:546-53. [PMID: 32951893 DOI: 10.1016/j.ygyno.2020.08.020] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
52 Dudek AZ, Baxstrom K, Bharadwaj S, Blaes A, Kulkarni A, Lou E, Nehru V, Rabinovich E, Shergill A, Viner M. Genomic Strategies for Personalized Cancer Therapy. Precision Medicine in Oncology 2020. [DOI: 10.1002/9781119432487.ch1] [Reference Citation Analysis]
53 Luo F, Wen Y, Zhou H, Li Z. Roles of long non-coding RNAs in cervical cancer. Life Sciences 2020;256:117981. [DOI: 10.1016/j.lfs.2020.117981] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
54 Uprety D, Adjei AA. KRAS: From undruggable to a druggable Cancer Target. Cancer Treatment Reviews 2020;89:102070. [DOI: 10.1016/j.ctrv.2020.102070] [Cited by in Crossref: 64] [Cited by in F6Publishing: 58] [Article Influence: 21.3] [Reference Citation Analysis]
55 Park KJ. Cervical adenocarcinoma: integration of HPV status, pattern of invasion, morphology and molecular markers into classification. Histopathology 2020;76:112-27. [PMID: 31846527 DOI: 10.1111/his.13995] [Cited by in Crossref: 33] [Cited by in F6Publishing: 21] [Article Influence: 11.0] [Reference Citation Analysis]
56 Pergialiotis V, Nikolaou C, Haidopoulos D, Frountzas M, Thomakos N, Bellos I, Papapanagiotou A, Rodolakis A. PIK3CA Mutations and Their Impact on Survival Outcomes of Patients with Cervical Cancer: A Systematic Review. Acta Cytol 2020;64:547-55. [PMID: 32683364 DOI: 10.1159/000509095] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
57 Martell K, McIntyre JB, Kornaga EN, Chan AMY, Phan T, Köbel M, Enwere EK, Dean ML, Ghatage P, Lees-Miller SP, Doll CM. PIK3CA mutation and CNV status and post-chemoradiotherapy survival in patients with cervical cancer. Gynecol Oncol 2020;158:776-84. [PMID: 32653099 DOI: 10.1016/j.ygyno.2020.06.506] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
58 Jenkins D, Molijn A, Kazem S, Pirog EC, Alemany L, de Sanjosé S, Dinjens W, Quint W. Molecular and pathological basis of HPV-negative cervical adenocarcinoma seen in a global study. Int J Cancer 2020;147:2526-36. [PMID: 32474915 DOI: 10.1002/ijc.33124] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
59 Reich O, Regauer S, Kashofer K. Possibly carcinogenic HPV subtypes are a cause of HSIL and negative clinical HPV tests - A European prospective single center study. Gynecol Oncol 2020;158:112-6. [PMID: 32354471 DOI: 10.1016/j.ygyno.2020.04.685] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
60 Małusecka E, Chmielik E, Suwiński R, Giglok M, Lange D, Rutkowski T, Mazurek AM. Significance of HPV16 Viral Load Testing in Anal Cancer. Pathol Oncol Res 2020;26:2191-9. [PMID: 32266586 DOI: 10.1007/s12253-020-00801-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
61 Litviakov NV, Ibragimova MK, Tsyganov MM, Shpileva OV, Churuksaeva ON, Kolomiets LA. Changes in the genetic landscape during the malignization of high grade squamous intraepithelial lesion into cervical cancer. Curr Probl Cancer 2020;44:100567. [PMID: 32201051 DOI: 10.1016/j.currproblcancer.2020.100567] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
62 Gutierrez-Silerio GY, Franco-Topete RA, Haramati J, Navarrete-Medina EM, Gutierrez-Franco J, Bueno-Topete MR, Bastidas-Ramirez BE, Ramos-Marquez ME, Del Toro-Arreola S. Positive staining of the immunoligand B7-H6 in abnormal/transformed keratinocytes consistently accompanies the progression of cervical cancer. BMC Immunol 2020;21:9. [PMID: 32138659 DOI: 10.1186/s12865-020-0341-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
63 Ichikawa R, Kawasaki R, Iwata A, Otani S, Nishio E, Nomura H, Fujii T. MicroRNA‑126‑3p suppresses HeLa cell proliferation, migration and invasion, and increases apoptosis via the PI3K/PDK1/AKT pathway. Oncol Rep 2020;43:1300-8. [PMID: 32323808 DOI: 10.3892/or.2020.7512] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
64 Tornesello ML, Faraonio R, Buonaguro L, Annunziata C, Starita N, Cerasuolo A, Pezzuto F, Tornesello AL, Buonaguro FM. The Role of microRNAs, Long Non-coding RNAs, and Circular RNAs in Cervical Cancer. Front Oncol 2020;10:150. [PMID: 32154165 DOI: 10.3389/fonc.2020.00150] [Cited by in Crossref: 92] [Cited by in F6Publishing: 98] [Article Influence: 30.7] [Reference Citation Analysis]
65 Jhingran A, Rodriguez AM. Neoplasms of the Cervix. Holland‐Frei Cancer Medicine 2019. [DOI: 10.1002/9781119000822.hfcm103.pub2] [Reference Citation Analysis]
66 Arafeh R, Samuels Y. PIK3CA in cancer: The past 30 years. Seminars in Cancer Biology 2019;59:36-49. [DOI: 10.1016/j.semcancer.2019.02.002] [Cited by in Crossref: 74] [Cited by in F6Publishing: 83] [Article Influence: 18.5] [Reference Citation Analysis]
67 Hirose S, Murakami N, Takahashi K, Kuno I, Takayanagi D, Asami Y, Matsuda M, Shimada Y, Yamano S, Sunami K, Yoshida K, Honda T, Nakahara T, Watanabe T, Komatsu M, Hamamoto R, Kato MK, Matsumoto K, Okuma K, Kuroda T, Okamoto A, Itami J, Kohno T, Kato T, Shiraishi K, Yoshida H. Genomic alterations in STK11 can predict clinical outcomes in cervical cancer patients. Gynecol Oncol 2020;156:203-10. [PMID: 31757465 DOI: 10.1016/j.ygyno.2019.10.022] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
68 Pors J, Ho J, Prentice L, Thompson E, Cochrane D, Gibbard E, Huntsman D, Gilks B, Hoang LN. c-KIT Analysis and Targeted Molecular Sequencing of Mesonephric Carcinomas of the Female Genital Tract. American Journal of Surgical Pathology 2020;44:495-502. [DOI: 10.1097/pas.0000000000001403] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
69 Li R, Yan Q, Tian P, Wang Y, Wang J, Tao N, Ning L, Lin X, Ding L, Liu J, Ma C. CBX7 Inhibits Cell Growth and Motility and Induces Apoptosis in Cervical Cancer Cells. Mol Ther Oncolytics 2019;15:108-16. [PMID: 31709304 DOI: 10.1016/j.omto.2019.09.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
70 Xing D, Liu Y, Park HJ, Baek I, Tran H, Cheang G, Novo J, Dillon J, Matoso A, Farmer E, Cheng MA, Tsai YC, Lombardo K, Conner MG, Vang R, Hung CF, Wu TC, Song W. Recurrent genetic alterations and biomarker expression in primary and metastatic squamous cell carcinomas of the vulva. Hum Pathol 2019;92:67-80. [PMID: 31437519 DOI: 10.1016/j.humpath.2019.08.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
71 Cao L, Wen H, Feng Z, Han X, Wu X. Distinctive clinicopathologic characteristics and prognosis for different histologic subtypes of early cervical cancer. Int J Gynecol Cancer 2019;29:1244-51. [PMID: 31422351 DOI: 10.1136/ijgc-2019-000556] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
72 Xing D, Zheng G, Schoolmeester JK, Li Z, Pallavajjala A, Haley L, Conner MG, Vang R, Hung CF, Wu TC, Ronnett BM. Next-generation Sequencing Reveals Recurrent Somatic Mutations in Small Cell Neuroendocrine Carcinoma of the Uterine Cervix. Am J Surg Pathol 2018;42:750-60. [PMID: 29505425 DOI: 10.1097/PAS.0000000000001042] [Cited by in Crossref: 40] [Cited by in F6Publishing: 47] [Article Influence: 10.0] [Reference Citation Analysis]
73 Razia S, Nakayama K, Nakamura K, Ishibashi T, Ishikawa M, Minamoto T, Iida K, Otsuki Y, Nakayama S, Ishikawa N, Kyo S. Clinicopathological and biological analysis of PIK3CA mutation and amplification in cervical carcinomas. Exp Ther Med 2019;18:2278-84. [PMID: 31410178 DOI: 10.3892/etm.2019.7771] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
74 Regauer S, Reich O, Kashofer K. Thin variant of high-grade squamous intraepithelial lesion - relationship with high-risk and possibly carcinogenic human papilloma virus subtypes and somatic cancer gene mutations. Histopathology 2019;75:405-12. [PMID: 30927371 DOI: 10.1111/his.13869] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
75 Su PH, Lai HC, Huang RL, Chen LY, Wang YC, Wu TI, Chan MWY, Liao CC, Chen CW, Lin WY, Chang CC. Paired Box-1 (PAX1) Activates Multiple Phosphatases and Inhibits Kinase Cascades in Cervical Cancer. Sci Rep 2019;9:9195. [PMID: 31235851 DOI: 10.1038/s41598-019-45477-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
76 Stolnicu S, Hoang L, Soslow RA. Recent advances in invasive adenocarcinoma of the cervix. Virchows Arch. 2019;475:537-549. [PMID: 31209635 DOI: 10.1007/s00428-019-02601-0] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 7.5] [Reference Citation Analysis]
77 Rojo-León V, García C, Valencia C, Méndez MA, Wood C, Covarrubias L. The E6/E7 oncogenes of human papilloma virus and estradiol regulate hedgehog signaling activity in a murine model of cervical cancer. Exp Cell Res 2019;381:311-22. [PMID: 31125556 DOI: 10.1016/j.yexcr.2019.05.024] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
78 Liu JF, Gray KP, Wright AA, Campos S, Konstantinopoulos PA, Peralta A, MacNeill K, Morrissey S, Whalen C, Dillon D, Matulonis UA. Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer. Gynecol Oncol 2019;154:95-101. [PMID: 31118140 DOI: 10.1016/j.ygyno.2019.05.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
79 Turashvili G, Park KJ. Cervical Glandular Neoplasia: Classification and Staging. Surg Pathol Clin 2019;12:281-313. [PMID: 31097105 DOI: 10.1016/j.path.2019.01.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
80 Bossler F, Hoppe-Seyler K, Hoppe-Seyler F. PI3K/AKT/mTOR Signaling Regulates the Virus/Host Cell Crosstalk in HPV-Positive Cervical Cancer Cells. Int J Mol Sci 2019;20:E2188. [PMID: 31058807 DOI: 10.3390/ijms20092188] [Cited by in Crossref: 35] [Cited by in F6Publishing: 43] [Article Influence: 8.8] [Reference Citation Analysis]
81 Rodriguez-Freixinos V, Ruiz-Pace F, Fariñas-Madrid L, Garrido-Castro AC, Villacampa G, Nuciforo P, Vivancos A, Dienstmann R, Oaknin A. Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer. ESMO Open 2019;4:e000444. [PMID: 30962959 DOI: 10.1136/esmoopen-2018-000444] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
82 Rodriguez-Freixinos V, Ruiz-Pace F, Fariñas-Madrid L, Garrido-Castro AC, Villacampa G, Nuciforo P, Vivancos A, Dienstmann R, Oaknin A. Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer. ESMO Open 2019;4:e000444. [PMID: 30962959 DOI: 10.1136/esmoopen-2018-000444] [Reference Citation Analysis]
83 Rodriguez-Freixinos V, Ruiz-Pace F, Fariñas-Madrid L, Garrido-Castro AC, Villacampa G, Nuciforo P, Vivancos A, Dienstmann R, Oaknin A. Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer. ESMO Open 2019;4:e000444. [PMID: 30962959 DOI: 10.1136/esmoopen-2018-000444] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
84 Nishio S, Mikami Y, Tokunaga H, Yaegashi N, Satoh T, Saito M, Okamoto A, Kasamatsu T, Miyamoto T, Shiozawa T, Yoshioka Y, Mandai M, Kojima A, Takehara K, Kaneki E, Kobayashi H, Kaku T, Ushijima K, Kamura T. Analysis of gastric-type mucinous carcinoma of the uterine cervix — An aggressive tumor with a poor prognosis: A multi-institutional study. Gynecologic Oncology 2019;153:13-9. [DOI: 10.1016/j.ygyno.2019.01.022] [Cited by in Crossref: 50] [Cited by in F6Publishing: 53] [Article Influence: 12.5] [Reference Citation Analysis]
85 Lin M, Ye M, Zhou J, Wang ZP, Zhu X. Recent Advances on the Molecular Mechanism of Cervical Carcinogenesis Based on Systems Biology Technologies. Comput Struct Biotechnol J 2019;17:241-50. [PMID: 30847042 DOI: 10.1016/j.csbj.2019.02.001] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 7.5] [Reference Citation Analysis]
86 Sahasrabudhe NM, van der Horst JC, Spaans V, Kenter G, de Kroon C, Bosse T, van Vliet SJ, Jordanova ES. MGL Ligand Expression Is Correlated to Lower Survival and Distant Metastasis in Cervical Squamous Cell and Adenosquamous Carcinoma. Front Oncol 2019;9:29. [PMID: 30761272 DOI: 10.3389/fonc.2019.00029] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
87 Pirog EC, Wright TC, Ronnett BM, Kurman RJ. Carcinoma and Other Tumors of the Cervix. Blaustein's Pathology of the Female Genital Tract 2019. [DOI: 10.1007/978-3-319-46334-6_6] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
88 Cameron JE, Hagensee M. HPV-Associated Oropharyngeal Cancer in the HIV/AIDS Patient. Cancer Treat Res 2019;177:131-81. [PMID: 30523624 DOI: 10.1007/978-3-030-03502-0_6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
89 Parra-herran C. Glandular Neoplasia of the Uterine Cervix and Its Related Lesions. Gynecologic and Obstetric Pathology, Volume 1 2019. [DOI: 10.1007/978-981-13-3016-2_13] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
90 Jonska-Gmyrek J, Gmyrek L, Zolciak-Siwinska A, Kowalska M, Fuksiewicz M, Kotowicz B. Pretreatment neutrophil to lymphocyte and platelet to lymphocyte ratios as predictive factors for the survival of cervical adenocarcinoma patients. Cancer Manag Res 2018;10:6029-38. [PMID: 30538552 DOI: 10.2147/CMAR.S178745] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
91 Li X, Cai Y. Methylation-Based Classification of Cervical Squamous Cell Carcinoma into Two New Subclasses Differing in Immune-Related Gene Expression. Int J Mol Sci 2018;19:E3607. [PMID: 30445744 DOI: 10.3390/ijms19113607] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
92 Bu W, Liu Z, Jiang W, Nagi C, Huang S, Edwards DP, Jo E, Mo Q, Creighton CJ, Hilsenbeck SG, Leavitt AD, Lewis MT, Wong STC, Li Y. Mammary Precancerous Stem and Non-Stem Cells Evolve into Cancers of Distinct Subtypes. Cancer Res 2019;79:61-71. [PMID: 30401712 DOI: 10.1158/0008-5472.CAN-18-1087] [Cited by in Crossref: 20] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
93 Hu Z, Ma D. The precision prevention and therapy of HPV-related cervical cancer: new concepts and clinical implications. Cancer Med 2018;7:5217-36. [PMID: 30589505 DOI: 10.1002/cam4.1501] [Cited by in Crossref: 96] [Cited by in F6Publishing: 106] [Article Influence: 19.2] [Reference Citation Analysis]
94 Nuryadi E, Sasaki Y, Hagiwara Y, Permata TBM, Sato H, Komatsu S, Yoshimoto Y, Murata K, Ando K, Kubo N, Okonogi N, Takakusagi Y, Adachi A, Iwanaga M, Tsuchida K, Tamaki T, Noda SE, Hirota Y, Shibata A, Ohno T, Tokino T, Oike T, Nakano T. Mutational analysis of uterine cervical cancer that survived multiple rounds of radiotherapy. Oncotarget 2018;9:32642-52. [PMID: 30220971 DOI: 10.18632/oncotarget.25982] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
95 Lachkar B, Minaguchi T, Akiyama A, Liu S, Zhang S, Xu C, Shikama A, Tasaka N, Sakurai M, Nakao S, Ochi H, Yoshikawa H, Satoh T. Prognostic significance of PIK3CA mutation in stage IIB to IVA cervical cancers treated by concurrent chemoradiotherapy with weekly cisplatin. Medicine (Baltimore) 2018;97:e11392. [PMID: 30075505 DOI: 10.1097/MD.0000000000011392] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
96 Jonska-Gmyrek J, Gmyrek L, Zolciak-Siwinska A, Kowalska M, Kotowicz B. Adenocarcinoma histology is a poor prognostic factor in locally advanced cervical cancer. Curr Med Res Opin 2019;35:595-601. [PMID: 30019594 DOI: 10.1080/03007995.2018.1502166] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
97 Jiang W, Xiang L, Pei X, He T, Shen X, Wu X, Yang H. Mutational analysis of KRAS and its clinical implications in cervical cancer patients. J Gynecol Oncol 2018;29:e4. [PMID: 29185262 DOI: 10.3802/jgo.2018.29.e4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
98 Meng Y, Liang H, Hu J, Liu S, Hao X, Wong MSK, Li X, Hu L. PD-L1 Expression Correlates With Tumor Infiltrating Lymphocytes And Response To Neoadjuvant Chemotherapy In Cervical Cancer. J Cancer 2018;9:2938-45. [PMID: 30123362 DOI: 10.7150/jca.22532] [Cited by in Crossref: 80] [Cited by in F6Publishing: 83] [Article Influence: 16.0] [Reference Citation Analysis]
99 Colombo I, Kurnit KC, Westin SN, Oza AM. Moving From Mutation to Actionability. American Society of Clinical Oncology Educational Book 2018. [DOI: 10.1200/edbk_199665] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
100 Herfs M, Roncarati P, Koopmansch B, Peulen O, Bruyere D, Lebeau A, Hendrick E, Hubert P, Poncin A, Penny W, Piazzon N, Monnien F, Guenat D, Mougin C, Prétet JL, Vuitton L, Segers K, Lambert F, Bours V, de Leval L, Valmary-Degano S, Quick CM, Crum CP, Delvenne P. A dualistic model of primary anal canal adenocarcinoma with distinct cellular origins, etiologies, inflammatory microenvironments and mutational signatures: implications for personalised medicine. Br J Cancer 2018;118:1302-12. [PMID: 29700411 DOI: 10.1038/s41416-018-0049-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
101 Kojima A, Shimada M, Mikami Y, Nagao S, Takeshima N, Sugiyama T, Teramoto N, Kiyokawa T, Kigawa J, Nishimura R; Sankai Gynecology Study Group. Chemoresistance of Gastric-Type Mucinous Carcinoma of the Uterine Cervix: A Study of the Sankai Gynecology Study Group. Int J Gynecol Cancer 2018;28:99-106. [PMID: 29206664 DOI: 10.1097/IGC.0000000000001145] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 7.8] [Reference Citation Analysis]
102 Barroilhet L, Matulonis U. The NCI-MATCH trial and precision medicine in gynecologic cancers. Gynecologic Oncology 2018;148:585-90. [DOI: 10.1016/j.ygyno.2018.01.008] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 7.2] [Reference Citation Analysis]
103 Kim HJ, Lee SY, Kim CY, Kim YH, Ju W, Kim SC. Subcellular localization of FOXO3a as a potential biomarker of response to combined treatment with inhibitors of PI3K and autophagy in PIK3CA-mutant cancer cells. Oncotarget 2017;8:6608-22. [PMID: 28036259 DOI: 10.18632/oncotarget.14245] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
104 Wongwarangkana C, Wanlapakorn N, Chansaenroj J, Poovorawan Y. Retinoic acid receptor beta promoter methylation and risk of cervical cancer. World J Virol 2018; 7(1): 1-9 [PMID: 29468136 DOI: 10.5501/wjv.v7.i1.1] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
105 Kumar L, Harish P, Malik PS, Khurana S. Chemotherapy and targeted therapy in the management of cervical cancer. Curr Probl Cancer 2018;42:120-8. [PMID: 29530393 DOI: 10.1016/j.currproblcancer.2018.01.016] [Cited by in Crossref: 66] [Cited by in F6Publishing: 59] [Article Influence: 13.2] [Reference Citation Analysis]
106 Serkies K, Jassem J. Systemic therapy for cervical carcinoma - current status. Chin J Cancer Res 2018;30:209-21. [PMID: 29861606 DOI: 10.21147/j.issn.1000-9604.2018.02.04] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
107 Femi OF. Genetic alterations and PIK3CA gene mutations and amplifications analysis in cervical cancer by racial groups in the United States. Int J Health Sci (Qassim) 2018;12:28-32. [PMID: 29623014] [Reference Citation Analysis]
108 Carvalho J, Pereira E, Marquevielle J, Campello MP, Mergny J, Paulo A, Salgado GF, Queiroz JA, Cruz C. Fluorescent light-up acridine orange derivatives bind and stabilize KRAS-22RT G-quadruplex. Biochimie 2018;144:144-52. [DOI: 10.1016/j.biochi.2017.11.004] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 6.8] [Reference Citation Analysis]
109 Tian J, Dong D, Liu Z, Zang Y, Wei J, Song J, Mu W, Wang S, Zhou M. Radiomics in Medical Imaging—Detection, Extraction and Segmentation. Intelligent Systems Reference Library 2018. [DOI: 10.1007/978-3-319-68843-5_11] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
110 Pirog EC, Wright TC, Ronnett BM, Kurman RJ. Carcinoma and Other Tumors of the Cervix. Blaustein's Pathology of the Female Genital Tract 2018. [DOI: 10.1007/978-1-4614-3165-7_6-2] [Reference Citation Analysis]
111 Takakura M, Matsumoto T, Nakamura M, Mizumoto Y, Myojyo S, Yamazaki R, Iwadare J, Bono Y, Orisaka S, Obata T, Iizuka T, Kagami K, Nakayama K, Hayakawa H, Sakurai F, Mizuguchi H, Urata Y, Fujiwara T, Kyo S, Sasagawa T, Fujiwara H. Detection of circulating tumor cells in cervical cancer using a conditionally replicative adenovirus targeting telomerase-positive cells. Cancer Sci 2018;109:231-40. [PMID: 29151279 DOI: 10.1111/cas.13449] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
112 Konathala GK, Mandarapu R, Godi S. Oncogenic mutations of PIK3CA and HRAS in carcinoma of cervix in South Indian women. Journal of Oncological Sciences 2017;3:112-6. [DOI: 10.1016/j.jons.2017.10.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
113 Seamon LG, Java JJ, Monk BJ, Penson RT, Brown J, Mannel RS, Oaknin A, Leitao MM, Eisenhauer EL, Long HJ, Liao SY, Tewari KS. Impact of tumour histology on survival in advanced cervical carcinoma: an NRG Oncology/Gynaecologic Oncology Group Study. Br J Cancer 2018;118:162-70. [PMID: 29182608 DOI: 10.1038/bjc.2017.400] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
114 Spaans VM, Nyoman Bayu Mahendra I, Purwoto G, Trietsch MD, Osse M, Ter Haar N, Peters AAW, Fleuren GJ, Jordanova ES. The landscape of somatic mutations in Indonesian cervical cancer is predominated by the PI3K pathway. Gynecol Oncol 2018;148:189-96. [PMID: 29113722 DOI: 10.1016/j.ygyno.2017.10.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
115 Dean M. From Gene to Therapy: Understanding Human Disease through Genetics. Colloquium Series on The Genetic Basis of Human Disease 2017;5:i-89. [DOI: 10.4199/c00154ed1v01y201707gbd008] [Reference Citation Analysis]
116 Litwin TR, Clarke MA, Dean M, Wentzensen N. Somatic Host Cell Alterations in HPV Carcinogenesis. Viruses 2017;9:E206. [PMID: 28771191 DOI: 10.3390/v9080206] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 6.8] [Reference Citation Analysis]
117 Chung TK, Cheung TH, Yim SF, Yu MY, Chiu RW, Lo KW, Lee IP, Wong RR, Lau KK, Wang VW, Worley MJ, Elias KM, Fiascone SJ, Smith DI, Berkowitz RS, Wong YF. Liquid biopsy of PIK3CA mutations in cervical cancer in Hong Kong Chinese women. Gynecologic Oncology 2017;146:334-9. [DOI: 10.1016/j.ygyno.2017.05.038] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 4.7] [Reference Citation Analysis]
118 Hodgson A, Amemiya Y, Seth A, Cesari M, Djordjevic B, Parra-Herran C. Genomic abnormalities in invasive endocervical adenocarcinoma correlate with pattern of invasion: biologic and clinical implications. Mod Pathol 2017;30:1633-41. [PMID: 28731050 DOI: 10.1038/modpathol.2017.80] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 4.7] [Reference Citation Analysis]
119 Bahrami A, Hasanzadeh M, Hassanian SM, ShahidSales S, Ghayour-Mobarhan M, Ferns GA, Avan A. The Potential Value of the PI3K/Akt/mTOR Signaling Pathway for Assessing Prognosis in Cervical Cancer and as a Target for Therapy. J Cell Biochem 2017;118:4163-9. [PMID: 28475243 DOI: 10.1002/jcb.26118] [Cited by in Crossref: 66] [Cited by in F6Publishing: 72] [Article Influence: 11.0] [Reference Citation Analysis]
120 Zou Y, Liu FY, Wu J, Wan L, Fang SF, Zhang ZY, Luo Y, Chen MH, Huang MZ, He M, Huang OP. Mutational analysis of the RAS/RAF/MEK/ERK signaling pathway in 260 Han Chinese patients with cervical carcinoma. Oncol Lett 2017;14:2427-31. [PMID: 28781678 DOI: 10.3892/ol.2017.6435] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
121 Reddy OL, Shintaku PI, Moatamed NA. Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas. Diagn Pathol 2017;12:45. [PMID: 28623908 DOI: 10.1186/s13000-017-0631-6] [Cited by in Crossref: 63] [Cited by in F6Publishing: 69] [Article Influence: 10.5] [Reference Citation Analysis]
122 Palisoul ML, Mullen MM, Feldman R, Thaker PH. Identification of molecular targets in vulvar cancers. Gynecol Oncol 2017;146:305-13. [PMID: 28536037 DOI: 10.1016/j.ygyno.2017.05.011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
123 Xu F, Zhang J, Hu G, Liu L, Liang W. Hypoxia and TGF-β1 induced PLOD2 expression improve the migration and invasion of cervical cancer cells by promoting epithelial-to-mesenchymal transition (EMT) and focal adhesion formation. Cancer Cell Int 2017;17:54. [PMID: 28507454 DOI: 10.1186/s12935-017-0420-z] [Cited by in Crossref: 40] [Cited by in F6Publishing: 46] [Article Influence: 6.7] [Reference Citation Analysis]
124 Small W Jr, Bacon MA, Bajaj A, Chuang LT, Fisher BJ, Harkenrider MM, Jhingran A, Kitchener HC, Mileshkin LR, Viswanathan AN, Gaffney DK. Cervical cancer: A global health crisis. Cancer 2017;123:2404-12. [PMID: 28464289 DOI: 10.1002/cncr.30667] [Cited by in Crossref: 480] [Cited by in F6Publishing: 552] [Article Influence: 80.0] [Reference Citation Analysis]
125 Li X. Emerging role of mutations in epigenetic regulators including MLL2 derived from The Cancer Genome Atlas for cervical cancer. BMC Cancer 2017;17:252. [PMID: 28390392 DOI: 10.1186/s12885-017-3257-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
126 Tewari KS, Monk BJ. Tumors of the Cervix. Textbook of Uncommon Cancer 2017. [DOI: 10.1002/9781119196235.ch43] [Reference Citation Analysis]
127 Martinho O, Silva-Oliveira R, Cury FP, Barbosa AM, Granja S, Evangelista AF, Marques F, Miranda-Gonçalves V, Cardoso-Carneiro D, de Paula FE, Zanon M, Scapulatempo-Neto C, Moreira MA, Baltazar F, Longatto-Filho A, Reis RM. HER Family Receptors are Important Theranostic Biomarkers for Cervical Cancer: Blocking Glucose Metabolism Enhances the Therapeutic Effect of HER Inhibitors. Theranostics 2017;7:717-32. [PMID: 28255362 DOI: 10.7150/thno.17154] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 3.7] [Reference Citation Analysis]
128 Ge Y, Guo M. Molecular Pathology of Cervical Dysplasia and Carcinoma. Molecular Pathology Library 2017. [DOI: 10.1007/978-3-319-57985-6_12] [Reference Citation Analysis]
129 Motohara T, Katabuchi H. Genomics in Gynecological Cancer: Future Perspective. Comprehensive Gynecology and Obstetrics 2017. [DOI: 10.1007/978-981-10-2489-4_2] [Reference Citation Analysis]
130 Roddy E, Chapman J. Genomic insights in gynecologic cancer. Current Problems in Cancer 2017;41:8-36. [DOI: 10.1016/j.currproblcancer.2016.11.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
131 Li X, Huang H, Guan Y, Gong Y, He CY, Yi X, Qi M, Chen ZY. Whole-exome sequencing predicted cancer epitope trees of 23 early cervical cancers in Chinese women. Cancer Med 2017;6:207-19. [PMID: 27998038 DOI: 10.1002/cam4.953] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
132 Prendergast EN, Elvin JA. Genomic profiling of gynecologic cancers and implications for clinical practice. Curr Opin Obstet Gynecol 2017;29:18-25. [PMID: 27984344 DOI: 10.1097/GCO.0000000000000335] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
133 Yokoi E, Mabuchi S, Takahashi R, Matsumoto Y, Kuroda H, Kozasa K, Kimura T. Impact of histological subtype on survival in patients with locally advanced cervical cancer that were treated with definitive radiotherapy: adenocarcinoma/adenosquamous carcinoma versus squamous cell carcinoma. J Gynecol Oncol 2017;28:e19. [PMID: 28028992 DOI: 10.3802/jgo.2017.28.e19] [Cited by in Crossref: 55] [Cited by in F6Publishing: 62] [Article Influence: 7.9] [Reference Citation Analysis]
134 Mandilaras V, Karakasis K, Clarke B, Oza A, Lheureux S. Rare tumors in gynaecological cancers and the lack of therapeutic options and clinical trials. Expert Opinion on Orphan Drugs 2016;5:71-83. [DOI: 10.1080/21678707.2017.1264300] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
135 Ferns DM, Heeren AM, Samuels S, Bleeker MCG, de Gruijl TD, Kenter GG, Jordanova ES. Classical and non-classical HLA class I aberrations in primary cervical squamous- and adenocarcinomas and paired lymph node metastases. J Immunother Cancer 2016;4:78. [PMID: 27895918 DOI: 10.1186/s40425-016-0184-3] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 5.3] [Reference Citation Analysis]
136 Sagae S, Monk BJ, Pujade-Lauraine E, Gaffney DK, Narayan K, Ryu SY, McCormack M, Plante M, Casado A, Reuss A, Chávez-Blanco A, Kitchener H, Nam BH, Jhingran A, Temkin S, Mileshkin L, Berns E, Scholl S, Doll C, Abu-Rustum NR, Lecuru F, Small W Jr; Gynecologic Cancer InterGroup Cervix Cancer brainstorming day. Advances and Concepts in Cervical Cancer Trials: A Road Map for the Future. Int J Gynecol Cancer 2016;26:199-207. [PMID: 26569057 DOI: 10.1097/IGC.0000000000000587] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 3.7] [Reference Citation Analysis]
137 Samuels S, Spaans VM, Osse M, Peters LA, Kenter GG, Fleuren GJ, Jordanova ES. Human Leukocyte Antigen-DR Expression is Significantly Related to an Increased Disease-Free and Disease-Specific Survival in Patients With Cervical Adenocarcinoma. Int J Gynecol Cancer 2016;26:1503-9. [PMID: 27654088 DOI: 10.1097/IGC.0000000000000783] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
138 Fleitas T, Ibarrola-villava M, Ribas G, Cervantes A. MassARRAY determination of somatic oncogenic mutations in solid tumors: Moving forward to personalized medicine. Cancer Treatment Reviews 2016;49:57-64. [DOI: 10.1016/j.ctrv.2016.07.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
139 Zhang J, Xu J, Wang G, Sun P, Yan T, Zhao X. WTIP interacts with BRCA2 and is essential for BRCA2 centrosome localization in cervical cancer cell. Arch Gynecol Obstet 2016;294:1311-6. [PMID: 27535760 DOI: 10.1007/s00404-016-4176-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
140 Liu J, Westin SN. Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know. Gynecol Oncol 2016;141:65-71. [PMID: 27016231 DOI: 10.1016/j.ygyno.2016.01.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
141 Shimada M, Nagao S, Fujiwara K, Takeshima N, Takizawa K, Shoji T, Sugiyama T, Yamaguchi S, Nishimura R, Kigawa J. Neoadjuvant chemotherapy with docetaxel and carboplatin followed by radical hysterectomy for stage IB2, IIA2, and IIB patients with non-squamous cell carcinoma of the uterine cervix. Int J Clin Oncol 2016;21:1128-35. [DOI: 10.1007/s10147-016-1010-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
142 Kim KP, Kim JE, Hong YS, Ahn SM, Chun SM, Hong SM, Jang SJ, Yu CS, Kim JC, Kim TW. Paired Primary and Metastatic Tumor Analysis of Somatic Mutations in Synchronous and Metachronous Colorectal Cancer. Cancer Res Treat 2017;49:161-7. [PMID: 27384156 DOI: 10.4143/crt.2015.490] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
143 Prigge ES, von Knebel Doeberitz M, Reuschenbach M. Clinical relevance and implications of HPV-induced neoplasia in different anatomical locations. Mutat Res Rev Mutat Res 2017;772:51-66. [PMID: 28528690 DOI: 10.1016/j.mrrev.2016.06.005] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 4.4] [Reference Citation Analysis]
144 Takeuchi S. Biology and treatment of cervical adenocarcinoma. Chin J Cancer Res. 2016;28:254-262. [PMID: 27198186 DOI: 10.21147/j.issn.1000-9604.2016.02.11] [Cited by in Crossref: 20] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
145 Frumovitz M, Burzawa JK, Byers LA, Lyons YA, Ramalingam P, Coleman RL, Brown J. Sequencing of mutational hotspots in cancer-related genes in small cell neuroendocrine cervical cancer. Gynecol Oncol 2016;141:588-91. [PMID: 27079212 DOI: 10.1016/j.ygyno.2016.04.001] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 5.0] [Reference Citation Analysis]
146 Heeren AM, Punt S, Bleeker MC, Gaarenstroom KN, van der Velden J, Kenter GG, de Gruijl TD, Jordanova ES. Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix. Mod Pathol 2016;29:753-63. [PMID: 27056074 DOI: 10.1038/modpathol.2016.64] [Cited by in Crossref: 159] [Cited by in F6Publishing: 173] [Article Influence: 22.7] [Reference Citation Analysis]
147 Husain RA, Ramakrishnan V. Global Variation of Human Papillomavirus Genotypes and Selected Genes Involved in Cervical Malignancies. Annals of Global Health 2018;81:675. [DOI: 10.1016/j.aogh.2015.08.026] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
148 Chung YL, Horng CF, Lee PI, Chen FL. Patterns of failure after use of (18)F-FDG PET/CT in integration of extended-field chemo-IMRT and 3D-brachytherapy plannings for advanced cervical cancers with extensive lymph node metastases. BMC Cancer 2016;16:179. [PMID: 26940959 DOI: 10.1186/s12885-016-2226-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
149 Xiang L, Li J, Jiang W, Shen X, Yang W, Wu X, Yang H. Comprehensive analysis of targetable oncogenic mutations in chinese cervical cancers. Oncotarget 2015;6:4968-75. [PMID: 25669975 DOI: 10.18632/oncotarget.3212] [Cited by in Crossref: 33] [Cited by in F6Publishing: 38] [Article Influence: 4.7] [Reference Citation Analysis]
150 Mackay HJ, Wenzel L, Mileshkin L. Nonsurgical management of cervical cancer: locally advanced, recurrent, and metastatic disease, survivorship, and beyond. Am Soc Clin Oncol Educ Book 2015;:e299-309. [PMID: 25993189 DOI: 10.14694/EdBook_AM.2015.35.e299] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
151 Pitt SC, Hernandez RA, Nehs MA, Gawande AA, Moore FD Jr, Ruan DT, Cho NL. Identification of Novel Oncogenic Mutations in Thyroid Cancer. J Am Coll Surg 2016;222:1036-1043.e2. [PMID: 27010584 DOI: 10.1016/j.jamcollsurg.2015.12.047] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
152 Qureshi R, Arora H, Biswas S, Perwez A, Naseem A, Wajid S, Gandhi G, Rizvi MA. Mutation analysis of EGFR and its correlation with the HPV in Indian cervical cancer patients. Tumour Biol 2016;37:9089-98. [PMID: 26762413 DOI: 10.1007/s13277-016-4789-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
153 D’andrilli G. Advances in Cervical Cancer and Ongoing Clinical Trials. Gynecological Cancers 2016. [DOI: 10.1007/978-3-319-32907-9_3] [Reference Citation Analysis]
154 Jung SH, Choi YJ, Kim MS, Baek IP, Lee SH, Lee AW, Hur SY, Kim TM, Lee SH, Chung YJ. Progression of naive intraepithelial neoplasia genome to aggressive squamous cell carcinoma genome of uterine cervix. Oncotarget 2015;6:4385-93. [PMID: 25738363 DOI: 10.18632/oncotarget.2981] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
155 Lee JY, Kim YT, Kim S, Lee B, Lim MC, Kim JW, Won YJ. Prognosis of Cervical Cancer in the Era of Concurrent Chemoradiation from National Database in Korea: A Comparison between Squamous Cell Carcinoma and Adenocarcinoma. PLoS One 2015;10:e0144887. [PMID: 26660311 DOI: 10.1371/journal.pone.0144887] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 4.5] [Reference Citation Analysis]
156 Liu J, Konstantinopoulos PA, Matulonis UA. Genomic testing and precision medicine--What does this mean for gynecologic oncology? Gynecol Oncol 2016;140:3-5. [PMID: 26657840 DOI: 10.1016/j.ygyno.2015.12.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
157 Wieringa HW, van der Zee AG, de Vries EG, van Vugt MA. Breaking the DNA damage response to improve cervical cancer treatment. Cancer Treat Rev 2016;42:30-40. [PMID: 26643553 DOI: 10.1016/j.ctrv.2015.11.008] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 5.1] [Reference Citation Analysis]
158 Scott CL, Mackay HJ, Haluska P Jr. Patient-derived xenograft models in gynecologic malignancies. Am Soc Clin Oncol Educ Book 2014;:e258-66. [PMID: 24857111 DOI: 10.14694/EdBook_AM.2014.34.e258] [Cited by in Crossref: 25] [Cited by in F6Publishing: 32] [Article Influence: 3.1] [Reference Citation Analysis]
159 Moore KN, Mannel RS. Is the NCI MATCH trial a match for gynecologic oncology? Gynecol Oncol 2016;140:161-6. [PMID: 26586415 DOI: 10.1016/j.ygyno.2015.11.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
160 Ngo C, Samuels S, Bagrintseva K, Slocker A, Hupé P, Kenter G, Popovic M, Samet N, Tresca P, von der Leyen H, Deutsch E, Rouzier R, Belin L, Kamal M, Scholl S; RAIDs consortium http://www.raids-fp7.eu/. From prospective biobanking to precision medicine: BIO-RAIDs - an EU study protocol in cervical cancer. BMC Cancer 2015;15:842. [PMID: 26531748 DOI: 10.1186/s12885-015-1801-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
161 Pinheiro C, Garcia EA, Morais-Santos F, Moreira MA, Almeida FM, Jubé LF, Queiroz GS, Paula ÉC, Andreoli MA, Villa LL, Longatto-Filho A, Baltazar F. Reprogramming energy metabolism and inducing angiogenesis: co-expression of monocarboxylate transporters with VEGF family members in cervical adenocarcinomas. BMC Cancer 2015;15:835. [PMID: 26525902 DOI: 10.1186/s12885-015-1842-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
162 Liang Y, Sun R, Li L, Yuan F, Liang W, Wang L, Nie X, Chen P, Zhang L, Gao L. A Functional Polymorphism in the Promoter of MiR-143/145 Is Associated With the Risk of Cervical Squamous Cell Carcinoma in Chinese Women: A Case-Control Study. Medicine (Baltimore) 2015;94:e1289. [PMID: 26252302 DOI: 10.1097/MD.0000000000001289] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 3.9] [Reference Citation Analysis]
163 Mersakova S, Nachajova M, Szepe P, Kasajova PS, Halasova E. DNA methylation and detection of cervical cancer and precancerous lesions using molecular methods. Tumour Biol 2016;37:23-7. [PMID: 26459314 DOI: 10.1007/s13277-015-4197-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
164 Bregar AJ, Growdon WB. Emerging strategies for targeting PI3K in gynecologic cancer. Gynecol Oncol 2016;140:333-44. [PMID: 26432040 DOI: 10.1016/j.ygyno.2015.09.083] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
165 Verlaat W, Snijders PJ, van Moorsel MI, Bleeker M, Rozendaal L, Sie D, Ylstra B, Meijer CJ, Steenbergen RD, Heideman DA. Somatic mutation in PIK3CA is a late event in cervical carcinogenesis. J Pathol Clin Res 2015;1:207-11. [PMID: 27499905 DOI: 10.1002/cjp2.27] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
166 Xiang L, Jiang W, Li J, Shen X, Yang W, Yang G, Wu X, Yang H. PIK3CA mutation analysis in Chinese patients with surgically resected cervical cancer. Sci Rep 2015;5:14035. [PMID: 26358014 DOI: 10.1038/srep14035] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
167 Mirkovic J, Sholl LM, Garcia E, Lindeman N, Macconaill L, Hirsch M, Dal Cin P, Gorman M, Barletta JA, Nucci MR, Mccluggage WG, Howitt BE. Targeted genomic profiling reveals recurrent KRAS mutations and gain of chromosome 1q in mesonephric carcinomas of the female genital tract. Mod Pathol 2015;28:1504-14. [DOI: 10.1038/modpathol.2015.103] [Cited by in Crossref: 77] [Cited by in F6Publishing: 81] [Article Influence: 9.6] [Reference Citation Analysis]
168 Molijn A, Jenkins D, Chen W, Zhang X, Pirog E, Enqi W, Liu B, Schmidt J, Cui J, Qiao Y, Quint W; Chinese HPV Typing Group. The complex relationship between human papillomavirus and cervical adenocarcinoma. Int J Cancer 2016;138:409-16. [PMID: 26334557 DOI: 10.1002/ijc.29722] [Cited by in Crossref: 47] [Cited by in F6Publishing: 51] [Article Influence: 5.9] [Reference Citation Analysis]
169 Bumrungthai S, Munjal K, Nandekar S, Cooper K, Ekalaksananan T, Pientong C, Evans MF. Epidermal growth factor receptor pathway mutation and expression profiles in cervical squamous cell carcinoma: therapeutic implications. J Transl Med 2015;13:244. [PMID: 26209091 DOI: 10.1186/s12967-015-0611-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
170 Spaans VM, Trietsch MD, Peters AA, Osse M, Ter Haar N, Fleuren GJ, Jordanova ES. Precise Classification of Cervical Carcinomas Combined with Somatic Mutation Profiling Contributes to Predicting Disease Outcome. PLoS One 2015;10:e0133670. [PMID: 26197069 DOI: 10.1371/journal.pone.0133670] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 4.0] [Reference Citation Analysis]
171 Fujiwara H, Yokota H, Monk B, Treilleux I, Devouassoux-Shisheboran M, Davis A, Kim JW, Mahner S, Stany M, Pignata S, Ray-Coquard I, Fujiwara K. Gynecologic Cancer InterGroup (GCIG) consensus review for cervical adenocarcinoma. Int J Gynecol Cancer 2014;24:S96-101. [PMID: 25341589 DOI: 10.1097/IGC.0000000000000263] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 4.0] [Reference Citation Analysis]
172 Perri T, Issakov G, Ben-Baruch G, Felder S, Beiner ME, Helpman L, Hogen L, Jakobson-Setton A, Korach J. Effect of treatment delay on survival in patients with cervical cancer: a historical cohort study. Int J Gynecol Cancer 2014;24:1326-32. [PMID: 25054445 DOI: 10.1097/IGC.0000000000000211] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 4.3] [Reference Citation Analysis]
173 Lou H, Villagran G, Boland JF, Im KM, Polo S, Zhou W, Odey U, Juárez-Torres E, Medina-Martínez I, Roman-Basaure E, Mitchell J, Roberson D, Sawitzke J, Garland L, Rodríguez-Herrera M, Wells D, Troyer J, Pinto FC, Bass S, Zhang X, Castillo M, Gold B, Morales H, Yeager M, Berumen J, Alvirez E, Gharzouzi E, Dean M. Genome Analysis of Latin American Cervical Cancer: Frequent Activation of the PIK3CA Pathway. Clin Cancer Res 2015;21:5360-70. [PMID: 26080840 DOI: 10.1158/1078-0432.CCR-14-1837] [Cited by in Crossref: 49] [Cited by in F6Publishing: 54] [Article Influence: 6.1] [Reference Citation Analysis]
174 Samuels S, Ferns DM, Meijer D, van Straalen JP, Buist MR, Zijlmans HJ, Kenter GG, Jordanova ES. High levels of soluble MICA are significantly related to increased disease-free and disease-specific survival in patients with cervical adenocarcinoma. Tissue Antigens 2015;85:476-83. [PMID: 25871737 DOI: 10.1111/tan.12562] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
175 Stevanović S, Draper LM, Langhan MM, Campbell TE, Kwong ML, Wunderlich JR, Dudley ME, Yang JC, Sherry RM, Kammula US, Restifo NP, Rosenberg SA, Hinrichs CS. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol 2015;33:1543-50. [PMID: 25823737 DOI: 10.1200/JCO.2014.58.9093] [Cited by in Crossref: 356] [Cited by in F6Publishing: 381] [Article Influence: 44.5] [Reference Citation Analysis]
176 Punt S, van Vliet ME, Spaans VM, de Kroon CD, Fleuren GJ, Gorter A, Jordanova ES. FoxP3(+) and IL-17(+) cells are correlated with improved prognosis in cervical adenocarcinoma. Cancer Immunol Immunother 2015;64:745-53. [PMID: 25795131 DOI: 10.1007/s00262-015-1678-4] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 4.9] [Reference Citation Analysis]
177 Wang J, Chai YL, Wang T, Liu JH, Dai PG, Liu Z. Genetic alterations of PIK3CA and tumor response in patients with locally advanced cervical squamous cell carcinoma treated with cisplatin-based concurrent chemoradiotherapy. Exp Mol Pathol 2015;98:407-10. [PMID: 25773678 DOI: 10.1016/j.yexmp.2015.03.014] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
178 Chen J. Signaling pathways in HPV-associated cancers and therapeutic implications: Signaling pathways in HPV-associated cancers. Rev Med Virol 2015;25:24-53. [DOI: 10.1002/rmv.1823] [Cited by in Crossref: 45] [Cited by in F6Publishing: 59] [Article Influence: 5.6] [Reference Citation Analysis]
179 Ito S, Tase T, Satoh K, Ueki M, Sato I, Sasano H. Gastric-type endocervical glandular neoplasms associated with aberrant p16 expression and K-RAS gene mutation in Peutz-Jeghers syndrome. Pathol Int 2014;64:283-8. [PMID: 24965111 DOI: 10.1111/pin.12173] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
180 Chung TK, Van Hummelen P, Chan PK, Cheung TH, Yim SF, Yu MY, Ducar MD, Thorner AR, MacConaill LE, Doran G, Pedamallu CS, Ojesina AI, Wong RR, Wang VW, Freeman SS, Lau TS, Kwong J, Chan LK, Fromer M, May T, Worley MJ Jr, Esselen KM, Elias KM, Lawrence M, Getz G, Smith DI, Crum CP, Meyerson M, Berkowitz RS, Wong YF. Genomic aberrations in cervical adenocarcinomas in Hong Kong Chinese women. Int J Cancer 2015;137:776-83. [PMID: 25626421 DOI: 10.1002/ijc.29456] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 4.0] [Reference Citation Analysis]
181 Groves IJ, Coleman N. Pathogenesis of human papillomavirus-associated mucosal disease. J Pathol. 2015;235:527-538. [PMID: 25604863 DOI: 10.1002/path.4496] [Cited by in Crossref: 86] [Cited by in F6Publishing: 93] [Article Influence: 10.8] [Reference Citation Analysis]
182 Nogueira-Rodrigues A, Ferreira CG. A brick in the wall. Cancer 2014;120:3586-7. [PMID: 25041767 DOI: 10.1002/cncr.28918] [Reference Citation Analysis]
183 Nogueira-rodrigues A, Ferreira CG, Bergmann A, de Aguiar SS, Thuler LCS. Comparison of adenocarcinoma (ACA) and squamous cell carcinoma (SCC) of the uterine cervix in a sub-optimally screened cohort: A population-based epidemiologic study of 51,842 women in Brazil. Gynecologic Oncology 2014;135:292-6. [DOI: 10.1016/j.ygyno.2014.08.014] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
184 Lyons YA, Frumovitz M, Soliman PT. Response to MEK inhibitor in small cell neuroendocrine carcinoma of the cervix with a KRAS mutation. Gynecol Oncol Rep 2014;10:28-9. [PMID: 26075998 DOI: 10.1016/j.gore.2014.09.003] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
185 Fujiwara K, Monk B, Devouassoux-shisheboran M. Adenocarcinoma of the Uterine Cervix: Why Is it Different? Curr Oncol Rep 2014;16. [DOI: 10.1007/s11912-014-0416-y] [Cited by in Crossref: 39] [Cited by in F6Publishing: 43] [Article Influence: 4.3] [Reference Citation Analysis]
186 Tornesello ML, Annunziata C, Buonaguro L, Losito S, Greggi S, Buonaguro FM. TP53 and PIK3CA gene mutations in adenocarcinoma, squamous cell carcinoma and high-grade intraepithelial neoplasia of the cervix. J Transl Med 2014;12:255. [PMID: 25220666 DOI: 10.1186/s12967-014-0255-5] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 4.3] [Reference Citation Analysis]
187 Rose PG, Java JJ, Whitney CW, Stehman FB, Lanciano R, Thomas GM. Locally advanced adenocarcinoma and adenosquamous carcinomas of the cervix compared to squamous cell carcinomas of the cervix in gynecologic oncology group trials of cisplatin-based chemoradiation. Gynecol Oncol 2014;135:208-12. [PMID: 25152438 DOI: 10.1016/j.ygyno.2014.08.018] [Cited by in Crossref: 63] [Cited by in F6Publishing: 68] [Article Influence: 7.0] [Reference Citation Analysis]
188 Halle MK, Krakstad C, Engerud H, Bertelsen B, Salvesen HB. Molecular profiling in fresh tissue with high tumor cell content promotes enrichment for aggressive adenocarcinomas in cervix. Pathol Res Pract 2014;210:774-8. [PMID: 25123963 DOI: 10.1016/j.prp.2014.07.002] [Reference Citation Analysis]
189 Steenbergen RD, Snijders PJ, Heideman DA, Meijer CJ. Clinical implications of (epi)genetic changes in HPV-induced cervical precancerous lesions. Nat Rev Cancer. 2014;14:395-405. [PMID: 24854082 DOI: 10.1038/nrc3728] [Cited by in Crossref: 236] [Cited by in F6Publishing: 247] [Article Influence: 26.2] [Reference Citation Analysis]
190 Dizon DS, Mackay HJ, Thomas GM, Werner TL, Kohn EC, Hess D, Rose PG, Covens AL. State of the science in cervical cancer: where we are today and where we need to go. Cancer. 2014;120:2282-2288. [PMID: 24737608 DOI: 10.1002/cncr.28722] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 3.4] [Reference Citation Analysis]
191 Spaans VM, Trietsch MD, Crobach S, Stelloo E, Kremer D, Osse EM, Haar NT, van Eijk R, Muller S, van Wezel T, Trimbos JB, Bosse T, Smit VT, Fleuren GJ. Designing a high-throughput somatic mutation profiling panel specifically for gynaecological cancers. PLoS One 2014;9:e93451. [PMID: 24671188 DOI: 10.1371/journal.pone.0093451] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 3.8] [Reference Citation Analysis]
192 Horowitz N, Matulonis U. Molecular Basis for Targeted Therapy in Gynecologic Cancer. Pathobiology of Human Disease 2014. [DOI: 10.1016/b978-0-12-386456-7.03907-1] [Reference Citation Analysis]
193 Chang AM, Nikiforova MN, Johnson JT, Bauman JE, Perez-Ordonez B, Seethala RR, Krane JF, Chiosea SI. Human papillomavirus-associated adenocarcinoma of the base of tongue: potentially actionable genetic changes. Head Neck Pathol 2014;8:151-6. [PMID: 24258618 DOI: 10.1007/s12105-013-0508-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]